Yuhan Valuation
Is A000105 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of A000105 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: A000105 (₩104000) is trading above our estimate of fair value (₩97242.9)
Significantly Below Fair Value: A000105 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for A000105?
Key metric: As A000105 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is A000105's PE Ratio? | |
|---|---|
| PE Ratio | 52.1x |
| Earnings | ₩165.69b |
| Market Cap | ₩8.62t |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 4.3x |
| Enterprise Value/EBITDA | 66.3x |
| PEG Ratio | 2.4x |
Price to Earnings Ratio vs Peers
How does A000105's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 43.2x | ||
A326030 SK Biopharmaceuticals | 130.2x | 49.7% | ₩7.5t |
A128940 Hanmi Pharm | 21.9x | 12.4% | ₩3.5t |
A069620 Daewoong Pharmaceutical | 14.3x | 14.6% | ₩1.5t |
A185750 Chong Kun Dang Pharmaceutical | 6.3x | -16.7% | ₩1.2t |
A000105 Yuhan | 52.1x | 21.9% | ₩8.6t |
Price-To-Earnings vs Peers: A000105 is expensive based on its Price-To-Earnings Ratio (52.1x) compared to the peer average (43.2x).
Price to Earnings Ratio vs Industry
How does A000105's PE Ratio compare vs other companies in the KR Pharmaceuticals Industry?
| 1 Company | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
A007370 Jin Yang Pharmaceutical | 2.4x | n/a | US$47.51m |
| 1 Company | Estimated Growth | Market Cap |
|---|
Price-To-Earnings vs Industry: A000105 is expensive based on its Price-To-Earnings Ratio (52.1x) compared to the KR Pharmaceuticals industry average (14.2x).
Price to Earnings Ratio vs Fair Ratio
What is A000105's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 52.1x |
| Fair PE Ratio | 27.8x |
Price-To-Earnings vs Fair Ratio: A000105 is expensive based on its Price-To-Earnings Ratio (52.1x) compared to the estimated Fair Price-To-Earnings Ratio (27.8x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Hugel
₩3.0t
Develops and manufactures biopharmaceuticals in South Korea and internationally.
A145020
₩271,000.00
7D
-1.8%
1Y
76.5%
J2KBIO
₩52.5b
A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.
A420570
₩9,180.00
7D
-4.8%
1Y
n/a
Ildong Pharmaceutical
₩339.7b
Develops, manufactures, and sells pharmaceutical products in South Korea.
A249420
₩12,160.00
7D
0.08%
1Y
-29.3%